Registration Dossier

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

In accordance with Regulation (EC) No 1907/2006 Annex VIII section 8.8.1, a toxicokinetics study is not required as assessment of the toxicokinetic behaviour of analogue substances has been derived from the relevant available information. This assessment is located within the endpoint summary for toxicokinetics, metabolism and distribution.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential
Absorption rate - oral (%):
Absorption rate - dermal (%):
Absorption rate - inhalation (%):

Additional information

13F-SFA is expected to be mainly absorbed via the oral route, or dermal route (assumed to be 10%). Following hydrolysis by esterase, 13F-SFA is proposed to be metabolized to acrylic acid and 6-2 FTOH. The primary excretory metabolite of acrylic acid is carbon dioxide. Potential intermediate metabolites of 6-2 FTOH are 6-2 FTCA, 6-2 FTUCA, 5-3 FTUCA and 5-3 FTCA, following elimination of HF, and the terminal metabolites of 6-2 FTOH are PFHxA and PFHpA (anticipated to be minor amounts), which are considered to contribute to the observed effects of 13F-SFA. Metabolites of acrylic acid are expected to distribute into liver, blood, or forestomach, and those of 6-2 FTOH will distribute into liver, blood, kidney and other tissues investigated (spleen, gonads and brain) as well as fat. It is expected that 13F-SFA has no significant potential for bioaccumulation in the body. All metabolites of 13F-SFA and parent compound can be excreted via respiration, urine and feces.